{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:36:53Z","timestamp":1786718213724,"version":"build-2736575974"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neural Regen Res"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/1673-5374.215245","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T01:26:38Z","timestamp":1505957198000},"page":"1422","source":"Crossref","is-referenced-by-count":14,"title":["Promises and pitfalls of immune-based strategies for Huntington's disease"],"prefix":"10.4103","volume":"12","author":[{"given":"AntonioLucio","family":"Teixeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GabrielaDelevati","family":"Colpo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ErinFurr","family":"Stimming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NataliaPessoa","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1673-5374.215245-1","doi-asserted-by":"crossref","unstructured":"Armstrong MJ, Miyasaki JM, American Academy of Neurology (2012) Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 79:597-603.","DOI":"10.1212\/WNL.0b013e318263c443"},{"key":"key-10.4103\/1673-5374.215245-2","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, Bates GP, Leavitt BR, et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 205:1869-1877.","DOI":"10.1084\/jem.20080178"},{"key":"key-10.4103\/1673-5374.215245-3","doi-asserted-by":"crossref","unstructured":"Bonelli RM, H\u00f6dl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19:337-342.","DOI":"10.1097\/00004850-200411000-00004"},{"key":"key-10.4103\/1673-5374.215245-4","doi-asserted-by":"crossref","unstructured":"Bye N, Habgood MD, Callaway JK, Malakooti N, Potter A, Kossmann T, Morganti-Kossmann MC (2007) Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. Exp Neurol 204:220-233.","DOI":"10.1016\/j.expneurol.2006.10.013"},{"key":"key-10.4103\/1673-5374.215245-5","doi-asserted-by":"crossref","unstructured":"Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801.","DOI":"10.1038\/80538"},{"key":"key-10.4103\/1673-5374.215245-6","doi-asserted-by":"crossref","unstructured":"Colpo GD, Ascoli BM, Wollenhaupt-Aguiar B, Pfaffenseller B, Silva EG, Cirne-Lima EO, Quevedo J, Kapczinski F, Rosa AR (2015) Mesenchymal stem cells for the treatment of neurodegenerative and psychiatric disorders. An Acad Bras Cienc 87:1435-1449.","DOI":"10.1590\/0001-3765201520140619"},{"key":"key-10.4103\/1673-5374.215245-7","doi-asserted-by":"crossref","unstructured":"Dutta S, Singh G, Sreejith S, Mamidi MK, Husin JM, Datta I, Pal R, Das AK (2013) Cell therapy: the final frontier for treatment of neurological diseases. CNS Neurosci Ther 19:5-11.","DOI":"10.1111\/cns.12027"},{"key":"key-10.4103\/1673-5374.215245-8","doi-asserted-by":"crossref","unstructured":"Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR (2012) Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol Dis 45:438-449.","DOI":"10.1016\/j.nbd.2011.09.003"},{"key":"key-10.4103\/1673-5374.215245-9","doi-asserted-by":"crossref","unstructured":"Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 6:31652.","DOI":"10.1038\/srep31652"},{"key":"key-10.4103\/1673-5374.215245-10","doi-asserted-by":"crossref","unstructured":"Hsiao HY, Chiu FL, Chen CM, Wu YR, Chen HM, Chen YC, Kuo HC, Chern Y (2014) Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease. Hum Mol Genet 23:4328-4344.","DOI":"10.1093\/hmg\/ddu151"},{"key":"key-10.4103\/1673-5374.215245-11","doi-asserted-by":"crossref","unstructured":"Huntington Study Group DOMINO Investigators (2010) A futility study of minocycline in Huntington's disease. Mov Disord 25:2219-2224.","DOI":"10.1002\/mds.23236"},{"key":"key-10.4103\/1673-5374.215245-12","doi-asserted-by":"crossref","unstructured":"Kalonia H, Kumar A (2011) Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. Life Sci 88:784-791.","DOI":"10.1016\/j.lfs.2011.02.020"},{"key":"key-10.4103\/1673-5374.215245-13","doi-asserted-by":"crossref","unstructured":"Kerkis I, Haddad MS, Valverde CW, Glosman S (2015) Neural and mesenchymal stem cells in animal models of Huntington's disease: past experiences and future challenges. Stem Cell Res Ther 6:232.","DOI":"10.1186\/s13287-015-0248-1"},{"key":"key-10.4103\/1673-5374.215245-14","doi-asserted-by":"crossref","unstructured":"Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, Chun W (2004) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 27:314-318.","DOI":"10.1007\/BF02980066"},{"key":"key-10.4103\/1673-5374.215245-15","doi-asserted-by":"crossref","unstructured":"Kolb-Sobieraj C, Gupta S, Weinstock-Guttman B (2014) Laquinimod therapy in multiple sclerosis: a comprehensive review. Neurol Ther 3:29-39.","DOI":"10.1007\/s40120-014-0017-6"},{"key":"key-10.4103\/1673-5374.215245-16","doi-asserted-by":"crossref","unstructured":"Kreutzberg GW (1996) Microglia: a sensor for pathological events in the CNS. Trends Neurosci 19:312-318.","DOI":"10.1016\/0166-2236(96)10049-7"},{"key":"key-10.4103\/1673-5374.215245-17","doi-asserted-by":"crossref","unstructured":"Labbadia J, Morimoto RI (2013) Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci 38:378-385.","DOI":"10.1016\/j.tibs.2013.05.003"},{"key":"key-10.4103\/1673-5374.215245-18","doi-asserted-by":"crossref","unstructured":"Langbehn DR, Hayden MR, Paulsen JS, the PREDICT-HD Investigators of the Huntington Study Group (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet 153B:397-408.","DOI":"10.1002\/ajmg.b.30992"},{"key":"key-10.4103\/1673-5374.215245-19","doi-asserted-by":"crossref","unstructured":"Luthi-Carter R (2003) Progress towards a vaccine for Huntington's disease. Mol Ther 7:569-570.","DOI":"10.1016\/S1525-0016(03)00107-2"},{"key":"key-10.4103\/1673-5374.215245-20","doi-asserted-by":"crossref","unstructured":"Noble W, Garwood CJ, Hanger DP (2009) Minocycline as a potential therapeutic agent in neurodegenerative disorders characterised by protein misfolding. Prion 3:78-83.","DOI":"10.4161\/pri.3.2.8820"},{"key":"key-10.4103\/1673-5374.215245-21","doi-asserted-by":"crossref","unstructured":"Norflus F, Nanje A, Gutekunst CA, Shi G, Cohen J, Bejarano M, Fox J, Ferrante RJ, Hersch SM (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis 17:319-325.","DOI":"10.1016\/j.nbd.2004.07.011"},{"key":"key-10.4103\/1673-5374.215245-22","doi-asserted-by":"crossref","unstructured":"Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638-1643.","DOI":"10.1212\/01.wnl.0000222734.56412.17"},{"key":"key-10.4103\/1673-5374.215245-23","doi-asserted-by":"crossref","unstructured":"Rocha NP, Ribeiro FM, Furr-Stimming E, Teixeira AL (2016) Neuroimmunology of Huntington's disease: revisiting evidence from human studies. Mediators Inflamm 2016:8653132.","DOI":"10.1155\/2016\/8653132"},{"key":"key-10.4103\/1673-5374.215245-24","doi-asserted-by":"crossref","unstructured":"Rossignol J, Fink K, Davis K, Clerc S, Crane A, Matchynski J, Lowrance S, Bombard M, Dekorver N, Lescaudron L, Dunbar GL (2014) Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioralsparing in a transgenic rat model of Huntington's disease. Stem Cells 32:500-509.","DOI":"10.1002\/stem.1508"},{"key":"key-10.4103\/1673-5374.215245-25","doi-asserted-by":"crossref","unstructured":"Salem H, Rocha NP, Colpo GD, Teixeira AL (2016) Moving from the dish to the clinical practice: a decade of lessons and perspectives from the pre-clinical and clinical stem cell studies for Alzheimer's disease. J Alzheimers Dis 53:1209-1230.","DOI":"10.3233\/JAD-160250"},{"key":"key-10.4103\/1673-5374.215245-26","doi-asserted-by":"crossref","unstructured":"Silvestroni A, Faull RL, Strand AD, M\u00f6ller T (2009) Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport 20:1098-1103.","DOI":"10.1097\/WNR.0b013e32832e34ee"},{"key":"key-10.4103\/1673-5374.215245-27","doi-asserted-by":"crossref","unstructured":"Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, Zauderer M, Hayden MR (2015) Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis 76:46-56.","DOI":"10.1016\/j.nbd.2015.01.002"},{"key":"key-10.4103\/1673-5374.215245-28","doi-asserted-by":"crossref","unstructured":"Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC, TRACK-HD investigators (2009) Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791-801.","DOI":"10.1016\/S1474-4422(09)70170-X"},{"key":"key-10.4103\/1673-5374.215245-29","doi-asserted-by":"crossref","unstructured":"Teixeira AL, Souza LC, Rocha NP, Furr-Stimming E, Lauterbach EC (2016) Revisiting the neuropsychiatry of Huntington's disease. Dement Neuropsychol 10:261-266.","DOI":"10.1590\/s1980-5764-2016dn1004002"},{"key":"key-10.4103\/1673-5374.215245-30","doi-asserted-by":"crossref","unstructured":"Terzi M, Altun G, \u015een S, Kocaman A, Kaplan AA, Yurt KK, Kaplan S (2017) The use of non-steroidal anti-inflammatory drugs in neurological diseases. J Chem Neuroanat","DOI":"10.1016\/j.jchemneu.2017.03.003"},{"key":"key-10.4103\/1673-5374.215245-31","doi-asserted-by":"crossref","unstructured":"doi: 10.1016\/j.jchemneu.2017.03.003.","DOI":"10.1016\/j.jchemneu.2017.03.003"},{"key":"key-10.4103\/1673-5374.215245-32","doi-asserted-by":"crossref","unstructured":"Thone J, Ellrichmann G, Seubert S, Peruga I, Lee DH, Conrad R, Hayardeny L, Comi G, Wiese S, Linker RA, Gold R (2012) Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 180:267-274.","DOI":"10.1016\/j.ajpath.2011.09.037"},{"key":"key-10.4103\/1673-5374.215245-33","doi-asserted-by":"crossref","unstructured":"Uccelli A, Benvenuto F, Laroni A, Giunti D (2011) Neuroprotective features of mesenchymal stem cells. Best Pract Res Clin Haematol 24:59-64.","DOI":"10.1016\/j.beha.2011.01.004"},{"key":"key-10.4103\/1673-5374.215245-34","doi-asserted-by":"crossref","unstructured":"Varrin-Doyer M, Zamvil SS, Schulze-Topphoff U (2014) Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol 262 Pt A:66-71.","DOI":"10.1016\/j.expneurol.2014.04.002"},{"key":"key-10.4103\/1673-5374.215245-35","doi-asserted-by":"crossref","unstructured":"Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM (2003) Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A 100:10483-10487.","DOI":"10.1073\/pnas.1832501100"},{"key":"key-10.4103\/1673-5374.215245-36","doi-asserted-by":"crossref","unstructured":"Weiss A, Trager U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, Tabrizi SJ (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest 122:3731-3736.","DOI":"10.1172\/JCI64565"},{"key":"key-10.4103\/1673-5374.215245-37","doi-asserted-by":"crossref","unstructured":"Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord 29:1434-1445.","DOI":"10.1002\/mds.26007"}],"container-title":["Neural Regeneration Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:32:27Z","timestamp":1786714347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1673-5374.215245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017]]}},"alternative-id":["215245"],"URL":"https:\/\/doi.org\/10.4103\/1673-5374.215245","relation":{},"ISSN":["1673-5374"],"issn-type":[{"value":"1673-5374","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}